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Both CD4
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Keywords: transplantation, tolerance, Treg, cell therapy, graft, gVhD, nsg mice inTrODUcTiOn Immunosuppressive regimens have significantly improved long-term graft survival in the last decades but they still cannot prevent the allograft from chronic graft dysfunction and they remain a significant obstacle for the welfare of transplanted patients, thus, in the last years, improvement of allograft survival has stagnated (1) . The identification in human of regulatory cell populations actively controlling immune responses in transplantation with high suppressive capacity and specificity toward donor antigens has generated revolutionizing therapeutic strategies in a number of diseases with a Treg/effector T cells (Teff) deregulation. The establishment of cellular therapy with regulatory cells has recently emerged as a promising future therapy in autoimmunity as well as bone marrow and solid organ transplantation (2) (3) (4) . Phase I studies in GVHD and solid organ transplantation have started with regulatory cells from different types (different CD4 + Tregs, macrophages, and DCs) without apparent toxicity (5-7), but to date, there are no clinical trials using CD8
+ Tregs despite abundant literature in animals models (8) (9) (10) . One limitation for translation of CD8 + Tregs in humans might be the lack of recognized marker such as Foxp3, a critical gene in the function of canonical CD4 + CD25 high CD12 7 low/− Tregs (11, 12) . However, the role and expression of Foxp3 has not been clearly defined for CD8
+ Tregs, and its function has not been clearly demonstrated (9, (13) (14) (15) (16) (17) (18) (19) (20) . Others have shown in mice that adoptive transfer of antigen-specific CD8 + Tregs were potent suppressors of fully MHC mismatch skin allograft and islet allograft (21, 22) . CD122
+ PD-1 + CD8 + Tregs efficiently inhibited skin allograft rejection in mice upon adoptive transfer and were more efficient at inhibiting islets allograft rejection than CD4 +
CD25
+ Tregs (23, 24) . Our own studies have shown in a rat model of CD40-CD40L blockade-induced allograft tolerance the critical role of a CD8
+ Tregs population expressing low/no level of CD45RC (8, 25) . Furthermore, treatment with anti-CD45RC depleted CD45RC
high cells, preserved CD45RC low/− CD8 + and CD4
+ Tregs and resulted in inhibition of solid organ rejection and of human GVHD in immune humanized mice (25) . We highlighted the biological role of IFNγ, IL-34, and Fibroleukin-2 (FGL-2) in the suppression exerted by CD8 + CD45RC low/− Tregs (8, 17, (26) (27) (28) .
In the present article, we aim to further characterize human CD8 + Tregs, to assess their potential for cell therapy in solid organ and bone marrow transplantation. We demonstrate here by extensive flow cytometry phenotyping, 3′digital gene expression (3′DGE) RNA-sequencing (DGE-RNAseq) and in vitro suppressive assays, the high suppressive capacity of a subset of CD8 +
CD45RC
low/− Tregs expressing Foxp3, GITR, IL-10, IL-34, TGFβ, and IFNγ at low levels in contrast to CD8 
low/− Tregs expressed Foxp3 + and high amount of cytokines and displayed high suppressive potential in immune humanized mice for both GVHD and human skin transplantation models. We show that expansion in the presence of rapamycin (Rapa) increased both the expansion yield and suppressive capacity of CD8 + CD45RC low/− Tregs. Analysis of CD8 + CD45RC low/− Tregs following expansion showed a selective gene signature both at transcriptomic and proteomic levels. Altogether our study highlights the unappreciated potential of CD8 + Tregs to control rejection in solid organ transplantation and GVHD.
MaTerials anD MeThODs healthy Volunteers Blood collection and PBMcs separation
Blood was collected at the Etablissement Français du Sang (Nantes, France) from healthy individuals ( Figure S1A, + cell sorting, respectively (29, 30) . Purity following sorting was always >97%.
Monoclonal antibodies and Flow cytometry
Antibodies used are listed in Table 1 . For stimulation, PBMCs were incubated with PMA (50 ng/ml) and ionomycine (1 µg/ml) for 7 h in the presence of Brefeldine A (10 µg/ml). Fc Receptors were blocked (BD Biosciences) and cells were permeabilized with Fix/Perm kit (Ebiosciences).
Fluorescence was measured with a LSR II or a Canto II cytometer (BD Biosciences, Mountain View, CA, USA) and analyzed with FLOWJO software (Tree Star, Inc., Ashland, OR, USA).
cpg Methylation of Foxp3
Pyrosequencing of bisulfite-modified genomic DNA was used to determine CpG methylation. Methylation analysis was conducted by EpigenDx for Foxp3 (Human FOXP3-ADS3576-ADS783) (http://epigendx.com/d/).
Mixed lymphocyte reaction

CD8
+ CD45RC low/− Tregs suppressive activity was assessed on syngeneic responder CD4 +
CD25
− T cells stimulated with allogeneic APCs, cDCs, or pDCs, at 1:1 ratio. CD8 + CD45RC low/− Tregs were stimulated overnight with coated anti-CD3 and soluble anti-CD28 MAbs (1 µg/ml each) in medium supplemented with 250U/ml IL-2 (Proleukin ® , Novartis) when indicated. 1,000 U/ml IL-2 (Proleukin ® , Novartis) or 50 µg/ml blocking mAbs or isotypic control mAbs were added at day 0 ( Table 1) . Transwell membrane (0.4 µM pores) (ThermoFisher Scientific) was used. Proliferation of CFSE-labeled (ThermoFisher Scientific) CD4
+ responder cells was analyzed by flow cytometry after 5 days of coculture in complete RPMI1640 medium supplemented with 5% AB serum, by 3′Dge rna-sequencing RNeasy-Mini Kits (Qiagen) were used to isolate total RNA that was then processed for RNA sequencing. Protocol of 3′DGE RNA-sequencing was performed as previously described (25) . ENA Study accession number PRJEB20793.
expansion of cD8
low/− Tregs were seeded at 3 × 10 5 /ml in complete RPMI1640 medium 10% AB serum, IL-2 (1,000 U/ml) and IL-15 (10 ng/ml), coated anti-CD3 mAb (1 µg/ml), soluble anti-CD28 mAb (1 µg/ml), and/or allogeneic APCs at 1:4 Tregs:APCs ratio. At day 7, expanded cells were diluted at 1.5 × 10 5 /ml and stimulated again. IL-2 and IL-15 cytokines were freshly added at days 0, 7, 10, and 12. Cyclosporine A (CsA, 45 ng/ml), Rapa (45 ng/ ml), methylprednisolone (MPr, 500 pg/ml), tacrolimus (2 ng/ml), or mycophenolate mofetil (MPA, 1 µg/ml) were used (31) (32) (33) (34) (35) . Suppressive activity was tested on CD8 + CD45RC low/− Tregs expanded more than 10-fold in 7 days. For long-term expansion, Tregs were stimulated again with coated anti-CD3 (1 µg/ml), soluble anti-CD28 MAbs (1 µg/ml) at days 14 and 21 and IL-2 and IL-15 cytokines were added every 2 days from days 7 to 28.
humanized Mouse Models
The 8-12-week-old NOD/SCID/IL2Rγ −/− (NSG) mice were bred in our own animal facilities in SPF conditions (accreditation number C44-278) and this study was carried out according to permit number APAFIS 3168 from ministry of research.
For xenogeneic GVHD experiments, 1.5 × 10 7 fresh PBMCs were intravenously injected with or without polyclonally expanded syngeneic CD8
+
CD45RC
low/− Tregs in 1.5 Gy-irradiated NSG mice. Human PBMCs engraftment was monitored in blood and GVHD development was evaluated by weight loss.
For skin transplantation, human skins were obtained from healthy donors from abdominoplasty surgery and transplantation was performed as previously described (36 Similarly to rats (8, 37, 38) , the CD45RC marker is differently expressed on CD8 + T cells in healthy individuals ( Figure 1A ) with no relation to age or gender ( Figure S1A ,B in Supplementary Material) and can identify two subsets. We have previously shown that CD45RC expression is not redundant with CD45RA, CD45RB and CD45RO expression, particularly for CD8 + and CD4 + Tregs (25) . Prestimulated sorted CD8 + CD45RC low/− Tregs showed a dose-dependent suppression of CD4 + T cell proliferation (>80% at a 1:1 effector:suppressor ratio), in contrast, prestimulated sorted CD8 + CD45RC high T cells did not significantly inhibit allogeneic CD4
+ T cell proliferation ( Figure 1B 
low/− Tregs. Altogether, these data demonstrate that CD8
Tregs exhibits a highly suppressive activity in contrast to CD8
+ CD45RC high T cell and that CD8 + CD45RC low/− Tregs act in a contact-dependent manner but do not use cytolysis to kill effector T cells or APCs.
cD8
+ cD45rc low/− Tregs cells express Foxp3 and secrete iFnγ, il-10, il-34, and TgFβ to inhibit anti-Donor immune responses
To determine the phenotype of CD8 + CD45RC low/− Tregs and compare its phenotype to previously described Treg subsets, we examined expression of various cell surface markers, intracellular cytokines, chemokine receptors, and transcription factors (Figure 2) 
CD45RC
high T cells (Figure 2A ; Figure S2B in Supplementary Material). Markers that were present in >50% of freshly isolated CD8
low/− Tregs were CD27, CD45RO, CD122, CD127, PD-1, and FGL-2 (Figure 2A ; Figure S2B in Supplementary Material), CD28 low and CD122 + CD8 + T cell subsets, previously described as CD8
+ Tregs in rodents and human (42, 43) did not correlate with CD8
+ CD45RC low/− T cells but were rather evenly 
CD25
− T cells stimulated with allogeneic APCs, in a range of effector:suppressor ratio. Proliferation was normalized to proliferation in the absence of Tregs. Two-way RM ANOVA, n = 3 for each group, ***p < 0.001. (D) Plasmacytoid dendritic cells (pDCs), conventional dendritic cells (cDCs), and total APCs were compared as stimulator cells for suppressive activity of Tregs. Proliferation was normalized to proliferation in the absence of Tregs. Two-way RM ANOVA, n = 3, *p < 0.05, **p < 0.01. (e) CD8 +
CD45RC
low/− Tregs were sorted, stimulated overnight with anti-CD3 and anti-CD28 MAbs, and compared for suppressive activity when physically separated from responder cells by a 0.4 µm transwell membrane (transwell, n = 8) vs. in contact with responder cells (coculture, n = 6). Proliferation was normalized to proliferation in the absence of Tregs with or without transwell membrane. APCs were added in both compartments. Two-way RM ANOVA, ****p < 0.0001. 
CD25
+ CD127 − Tregs). Figure 2G ). Other surface markers such as CD38, HLA-DR, CD45RA, CD127, CD197, CD27, CD28, and CD25 that were used to separate a positive and negative fraction did not allow identification of a significantly more suppressive subset ( Figure  S3A Altogether, these data suggest that CD8 low/− Tregs were sorted from healthy volunteers fresh blood, stimulated overnight with anti-CD3 and anti-CD28 MAbs, sorted again on IFNγ and IL-10 secretion and tested for suppressive activity in a range of effector:suppressor ratio. Proliferation was normalized to proliferation in the absence of Tregs. Two-way row-matched (RM) ANOVA, n = 10, *p < 0.05, **p < 0.01, ****p < 0.0001. (g) CD8 + CD45RC low/− Tregs were sorted from healthy volunteers' fresh blood, stimulated overnight with anti-CD3 and anti-CD28 MAbs, sorted again on GITR expression and tested for suppressive activity in a range of effector:suppressor ratio. Proliferation was normalized to proliferation in the absence of Tregs. Two-way RM ANOVA, n = 3, **p < 0.01. (h) Blocking Abs to TGFβ, IFNγ, IFNγ-R were added at day 0 of coculture. Proliferation in the presence of freshly sorted CD8 + CD45RC low/− Tregs was normalized to proliferation in the absence of Tregs. Wilcoxon matched-pairs signed rank test, two-tailed, left, n = 21-23; right, n = 10, **p < 0.01, ***p < 0.001. (Figure 3B ) compared to a polyclonal stimulation (anti-CD3/28) and high dose of IL-2 (1,000 U/ml) and IL-15 (10 ng/ml) ( Figure 3C ). Expansion at ratio 1:4 with APCs or anti-CD3/28 resulted in equivalent expansion yield, up to 2,000-fold in 14 days (Figures 3B,C) . Interestingly, CD8
Tregs isolated from frozen PBMCs expanded 10-fold more than CD8 + CD45RC low/− Tregs isolated from freshly isolated PBMCs ( Figure 3D) . Importantly, both allogeneic and anti-CD3/28 expanded CD8
low/− Tregs were significantly more efficient at suppressing an allogeneic immune response compared to fresh CD8 + CD45RC low/− Tregs (at a 1:1 cell ratio, 88 and 75 vs. 32% suppression, respectively) ( Figures 1C and 3E) .
CD8
+ CD45RC low/− Tregs sorted from fresh or thawed PBMCs were equally suppressive following expansion (data not shown).
Expanded CD8
+ CD45RC low/− Tregs did not increase their cytotoxic activity compared to fresh CD8 + CD45RC low/− Tregs toward allogeneic APCs (Figures 1G and 3F) , demonstrating that the superior suppressive capacity acquired upon expansion was not due to increased killing activity of the CD8 + CD45RC low/− Tregs. We tested the effect of immunosuppressive drugs (IS) (at concentrations used in the clinic) on Tregs survival 7 days following the 14 days expansion ( Figure S4B in Supplementary Material) and observed no significant effect on Tregs survival. Next, we tested the effect of the ISs during the 14 days expansion on the expansion yield and suppressive function score of CD8
low/− Tregs ( Figure 3G ; Figure S4C in Supplementary Material). Each IS was added or not (NT) during 14 days or combined together subsequently (i.e., days 0-7 CsA, then days 7-14 MPr is labeled CsAMPr in the upper left corner of Figure 3G ). We observed a striking beneficial effect of Rapa on both expansion fold and suppression capacity when the expansion was performed during 14 days in the presence of Rapa or if Rapa was at least used during the first 7 days of the expansion (Rapa-MPr, Rapa-Tacro, Rapa-NT, RapaCsA) (Figure 3G , right; Figure S4C do ( Figure 4E) . As FOXP3, genes commonly associated with Tregs suppressive function such as CTLA4, GITR, LAG3, IFNG, GZMB, IL2RA (CD25), CD38, TNFRSF9 (CD137) were upregulated both at transcriptomic and proteomic levels, while IL7RA (CD127) was downregulated. Other genes were related to surface markers and costimulation molecules such as TNFRSF9 (4-1BB), TNFRSF4 (OX40L), TNFRSF11A (RANK), TNFRSF8 (CD30), CD70, CD38, CD59, CD109, CD80, and CD58 were upregulated, while genes associated with activation such as CD28 and CD69 were significantly downregulated ( Figure 4E) . To gain insight into the mechanisms of action of expanded CD8 + CD45RC
low/− Tregs, we analyzed in detail the cytokines, chemokines, and granzymes that are overexpressed. We found a panel of cytokines including IFNγ and others such as CSF1 that we have observed upregulated by CD8 + CD45RC low/− Tregs in a model of tolerance in rat transplantation (25) , as well as a number of chemokines associated with Tregs and ligand to CCR5 including CCL3, CCL4, CCL8, as well as the chemokine receptors CCR3 and CCR2 influencing the migration pattern of Tregs. In contrast, although we observed the upregulation of GZMB (granzyme), we observed the downregulation of GZMK and GZMM and unaltered expression of PRF-1 (perforin).
Altogether, our data demonstrate a distinct phenotype and transcriptional signature of CD8
low/− Tregs following + CD45RC low/− Tregs were expanded with anti-CD3/CD28, IL-2, and IL-15 for 14 days and analyzed for expression of activation and exhaustion markers or cytokines and Treg-associated markers after a 7 h PMA-ionomycin stimulation when indicated (n = 3-7) and compared to non-expanded CD8 + CD45RC low/− Tregs (n = 5-52). Mann-Whitney two-tailed test, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. (B) CD8 + CD45RC low/− Tregs were analyzed for differentiation state basing on CCR7, CD45RA, CD27, and CD28 expression after expansion ("expanded," n = 5) as compared to before expansion ("fresh," n = 14), both without stimulation. Mann-Whitney two-tailed test, *p < 0.05, **p < 0.01. (c) Principal component analysis (PCA) of fresh vs. expanded CD8
Volcano plot representation of differential expression between fresh and expanded Tregs. Genes were colored when considered as differentially expressed, with adjusted p-value < 0.05 and two fold change. Using fresh CD8 + CD45RC low/− Tregs as a reference, green genes are downregulated and orange genes upregulated. (e) 3′ digital gene expression RNA-sequencing analysis was performed on CD8 + CD45RC low/− Tregs before and after expansion for 14 days. Expression levels of differentially expressed genes are presented as a heatmap; low expression levels are in blue, mean expression levels are in white and high expression levels are in red. Individual samples are numbered 1-11. expansion, supporting a potential increased suppressive activity with several regulatory genes and consolidate the demonstration that the expansion process adequately enriched in CD8 + CD45RC low/− Tregs with an improved regulatory activity suitable for transplantation.
Polyclonal expanded cD8
+ cD45rc
low/− Tregs efficiently Delay Xenogeneic gVhD and allogeneic human skin graft rejection in immune humanized Mice
We finally assessed the suppressive potential of expanded CD8 + CD45RC low/− Tregs using two distinct models of human immune responses in NSG (NOD-Scid-IL-2Rγ -/-) mice, rejection of human skin grafts following injection of allogeneic human PBMCs ( Figure 5A ; Figure S6A in Supplementary Material) and xenogeneic GVHD following injection of human PBMCs ( Figure 5B) . Interestingly, we observed in both cases that cotransfer of 14 days polyclonally expanded CD8 + CD45RC low/− Tregs significantly inhibited skin graft rejection (Figure 5A ), as well as GVHD ( Figure 5B ) and for both in a dose-dependent manner at 1:2 and 1:4 ratios, demonstrating the potential of the CD8 + CD45RC low/− Tregs as a cell therapy. Importantly, expanded CD8 + CD45RC low/− Tregs administration alone did not trigger GVHD proving that they display low cytotoxic activity ( Figure 5B ). Mice were in all cases, including those that did not develop graft rejection, well engrafted with human leukocytes ( Figure S6C in Supplementary Material).
We next tested the suppressive capacity of CD8 Figure 3D) .
Altogether, our data demonstrate here that CD8 + CD45RC (52) . ICOS and HLA-DR are markers that have also been associated with higher regulatory function of CD4 + Tregs and used to discriminate subsets of regulatory CD4
+ cells (53, 54) . We observed here that these two markers are expressed at low levels before expansion but are significantly upregulated upon expansion, thus ICOS and HLA-DR cannot be used to discriminate subsets of CD8 + Tregs, but can be associated with higher suppressive function. Looking for CD8
+ Tregs markers, we demonstrate that they are enriched within the CD45RC low/− subset. We have recently demonstrated that CD45RC is not expressed, or at low level by Tregs (both CD4
+ and CD8 + in rats and humans) and we have demonstrated that a short-term anti-CD45RC mAb therapy can induce transplant tolerance by depleting Teff while allowing activation and amplification of CD8 + and CD4 + Tregs (25) . Our DGE-RNAseq data and flow cytometry analysis have evidenced a number of potential markers for Tregs including CTLA4, GITR, LAG3, and NRP1. GITR is a known marker for CD4
+ Tregs that has been involved in thymic Treg (tTreg) differentiation and expansion in mice and humans (55 (63) . These features for antigen recognition for CD8 + Tregs were key to exert inhibitory activity and demonstrating that pDCs have superior protolerogenic activity (64, 65) . The identification of antigens recognized by Tregs is an important objective to increase their activity and in a rat allograft transplantation model, we identified MHC class II donor-derived antigens presented by recipient MHC-I molecules to CD8 + CD45RC low/− Tregs (28). We also demonstrated that administration of these donor peptides induced CD8 + Tregs and transplant tolerance (28) . The recent use of chimeric antigen receptor with donor HLA specificity has been recently used to redirect CD4 + Tregs bypassing the natural TCR (66) (67) (68) .
We set up a protocol of expansion of CD8 + CD45RC low/− Tregs in the presence of high-dose IL-2 and IL-15. IL-15 is known growth factor of CD8 + T cells that promote survival and activation and a potent inducer of Tregs (both CD4 + and CD8 + Tregs) (24, (69) (70) (71) . Another interesting finding was that Rapa might be beneficial to improve both expansion and function of CD8 + CD45RC low/− Tregs in vitro. Rapa has been shown to be beneficial in vivo for both CD8
+ and CD4 + Tregs in mice by increasing stability of Foxp3 (72) and to increase numbers of CD8 + CD28 − Tregs in kidney transplanted patients treated with Rapa (73) . In the context of cell therapy in transplantation, our data suggest that expansion in the presence of Rapa and coadministration with Rapa could be beneficial. We demonstrated the potential of expanded CD8 + CD45RC low/− Tregs as a cellular therapy in two models of human immune responses in NSG humanized mice rejecting either allogeneic human skin graft or developing an acute xenogeneic GVHD. CD8 + CD45RC
low/− Tregs could, in a dose-dependent manner, inhibit GVHD and skin graft rejection indefinitely for some of the recipients, suggesting even inhibition of chronic graft rejection and a high potential for CD8 + Tregs cell-based therapy. 
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